NCT01450124View on ClinicalTrials.gov

Safety, Tolerability And Mechanism Of Action Of Boswellic Acids (BA) In Multiple Sclerosis (SABA)

PHASE2CompletedINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

September 30, 2011

Primary Completion Date

December 31, 2014

Study Completion Date

December 31, 2014

Conditions
Relapsing Remitting Multiple Sclerosis
Interventions
DRUG

Boswellic acids (BOSWELAN)

8 months of treatment at a t.i.d. (Ter In Die (Latin: Three Times A Day) dose of between 400-1600 mg Boswelan

Trial Locations (2)

10117

NeuroCure Clinical Research Center (NCRC), Berlin

20246

University Medical Centre Hamburg-Eppendorf, Hamburg

All Listed Sponsors
lead

Universitätsklinikum Hamburg-Eppendorf

OTHER

NCT01450124 - Safety, Tolerability And Mechanism Of Action Of Boswellic Acids (BA) In Multiple Sclerosis (SABA) | Biotech Hunter | Biotech Hunter